CJC-1295 vs Ipamorelin

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce and release growth hormone. It is available in two forms: CJC-1295 without DAC has a half-life of approximately 30 minutes, while the DAC (Drug Affinity Complex) version extends the half-life to around 8 days, providing sustained growth hormone elevation. It works by amplifying the natural GHRH signal rather than replacing it. Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin, the hunger hormone, to trigger pulsatile growth hormone release from the pituitary. What sets ipamorelin apart from other ghrelin mimetics is its selectivity: it stimulates growth hormone release without significantly affecting cortisol or prolactin levels. This makes it one of the cleanest growth hormone peptides available with minimal adverse effects.

CJC-1295

Mechanism GHRH analog
GH Release Sustained elevation
Half-life 30 min (no DAC) / 8 days (with DAC)
Cortisol Impact Minimal
Best For Sustained GH elevation
Starting Price $19
Synergy Often combined with ipamorelin

Ipamorelin

Mechanism Ghrelin mimetic
GH Release Pulsatile release
Half-life ~2 hours
Cortisol Impact None
Best For Targeted GH pulses
Starting Price $15
Synergy Often combined with CJC-1295

The Verdict

CJC-1295 and ipamorelin work through fundamentally different mechanisms that are highly complementary. CJC-1295 provides sustained baseline GH elevation, while ipamorelin triggers pulsatile GH spikes that more closely mimic endogenous release patterns. Used alone, ipamorelin is often preferred for its selective profile and lower cost, while CJC-1295 with DAC appeals to researchers wanting less frequent administration. The combination is one of the most popular GH secretagogue stacks in peptide research.

Explore These Products

CJC-1295

A synthetic GHRH analog studied for its ability to sustain elevated growth hormone levels in research models.

View Details →

Ipamorelin

A selective growth hormone secretagogue that mimics ghrelin, studied for its ability to release GH without affecting cortisol or prolactin levels.

View Details →

CJC-1295 vs Ipamorelin — FAQ

What is the difference between CJC-1295 with and without DAC?
CJC-1295 without DAC (also called Mod GRF 1-29) has a shorter half-life and produces pulsatile GH release, making it suited for stacking with ipamorelin. The DAC version provides sustained release over several days but produces a less pulsatile GH pattern. Most research protocols use the no-DAC version for combination studies.
What is a common research protocol for CJC-1295 and ipamorelin?
Research protocols typically administer both peptides during periods of low metabolic activity. Some protocols include multiple daily administrations. The timing is chosen to align with endogenous GH secretion patterns in the study model.
How long are typical CJC-1295 and ipamorelin research cycles?
Typical research protocols run 8-12 weeks followed by a 4-week washout period. Some protocols continue at lower concentrations. Changes in GH-related biomarkers are often detectable within the first 2-3 weeks, while downstream effects typically become measurable around weeks 6-8.
Do CJC-1295 or ipamorelin affect endogenous GH production?
Both peptides stimulate the pituitary to release GH rather than introducing exogenous growth hormone, preserving endogenous production pathways. However, extended administration at high concentrations could theoretically cause receptor desensitization, which is why cycling protocols are commonly used in research.

References

Primary sources for key clinical and regulatory claims on this page.

  1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — PubMed / J Clin Endocrinol Metab . Primary source for the sustained GH and IGF-1 elevation and multiday half-life often cited for CJC-1295.
  2. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus — PubMed / J Pharmacol Exp Ther . Primary source describing ipamorelin as a selective ghrelin mimetic and growth-hormone secretagogue.

Keep Researching

Use the surrounding category and guide pages to move from a side-by-side comparison into the broader decision path.

Research Peptides CategoryGrowth-Hormone Hub
Updated March 2026. This comparison is reviewed for catalog accuracy, sourcing language, and consistency with our public quality standards. It is an educational summary for research reference only. Read our Editorial Standards.

Ready to order?

Pick your product and check out in under 3 minutes.

Shop Now